{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:34:34Z","timestamp":1789518874197,"version":"build-2803163510"},"reference-count":316,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Drug resistance represents one of the most critical challenges in modern medicine, undermining the efficacy of therapies across both bacterial infections and cancer. Although these conditions arise in fundamentally distinct biological systems, they are governed by shared evolutionary pressures that drive the emergence and selection of resistant populations. This narrative review provides an integrative, cross-disciplinary perspective on drug resistance, focusing on bacteria and cancer and emphasizing the shared evolutionary and molecular mechanisms underlying treatment failure in both domains. Key resistance strategies include efflux-mediated drug export, target modification, enzymatic drug inactivation, metabolic reprogramming, epigenetic and transcriptional plasticity, and protection conferred by specialized microenvironments. These processes are further reinforced by phenotypic heterogeneity, including bacterial persister cells and cancer stem-like cells, which contribute to recurrence and multidrug resistance. Collectively, these parallels define drug resistance as a convergent evolutionary phenomenon driven by adaptability under selective pressure. Recognizing these shared mechanisms reveals important translational opportunities for therapeutic intervention. Strategies such as combination therapy, drug repurposing, nanotechnology-enabled delivery systems, and host-directed approaches offer promising avenues to prevent, delay, or overcome resistance. By integrating insights from microbiology and oncology, this review proposes a unified framework for resistance biology and highlights the potential of cross-disciplinary strategies to improve treatment durability and clinical outcomes.<\/jats:p>","DOI":"10.3390\/ijms27104239","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:49:09Z","timestamp":1778572149000},"page":"4239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-8839","authenticated-orcid":false,"given":"Christos","family":"Papaneophytou","sequence":"first","affiliation":[{"name":"Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, Nicosia 2417, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1021\/acs.chemrev.1c00118","article-title":"Introduction: Drug Resistance","volume":"121","author":"Schiffer","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Salam, M.A., Al-Amin, M.Y., Salam, M.T., Pawar, J.S., Akhter, N., Rabaan, A.A., and Alqumber, M.A.A. (2023). Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare, 11.","DOI":"10.20944\/preprints202305.0555.v1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/microbiolres14020037","article-title":"Drug Resistance: An Incessant Fight against Evolutionary Strategies of Survival","volume":"14","year":"2023","journal-title":"Microbiol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70447","DOI":"10.1002\/mco2.70447","article-title":"Antibiotic Resistance: A Genetic and Physiological Perspective","volume":"6","author":"Elbaiomy","year":"2025","journal-title":"MedComm"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nrc3039","article-title":"An analogy between the evolution of drug resistance in bacterial communities and malignant tissues","volume":"11","author":"Lambert","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"aad3292","DOI":"10.1126\/science.aad3292","article-title":"Multidrug evolutionary strategies to reverse antibiotic resistance","volume":"351","author":"Baym","year":"2016","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Requesens, M., Foijer, F., Nijman, H.W., and de Bruyn, M. (2024). Genomic instability as a driver and suppressor of anti-tumor immunity. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1462496"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, \u00c1., Dinis-Oliveira, R.J., and Dias da Silva, D. (2024). An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms, 12.","DOI":"10.3390\/microorganisms12091920"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: Scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5737\/23688076354590","article-title":"Therapeutic breakthroughs in oncology: Enhancing treatment and management","volume":"35","author":"Eskandar","year":"2025","journal-title":"Can. Oncol. Nurs. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e27984","DOI":"10.1016\/j.heliyon.2024.e27984","article-title":"Unraveling resistance mechanisms in combination therapy: A comprehensive review of recent advances and future directions","volume":"10","year":"2024","journal-title":"Heliyon"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e71077","DOI":"10.1002\/hsr2.71077","article-title":"The Global Challenge of Antimicrobial Resistance: Mechanisms, Case Studies, and Mitigation Approaches","volume":"8","author":"Nazir","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e000378","DOI":"10.1136\/bmjgh-2017-000378","article-title":"Mapping global policy discourse on antimicrobial resistance","volume":"2","author":"Wernli","year":"2017","journal-title":"BMJ Glob. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"dlae208","DOI":"10.1093\/jacamr\/dlae208","article-title":"The social burden of antimicrobial resistance: What is it, how can we measure it, and why does it matter?","volume":"7","author":"Keenan","year":"2025","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_17","unstructured":"World Health Organization (2026, March 15). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2022. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240062702."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"de Kraker, M.E., Stewardson, A.J., and Harbarth, S. (2016). Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002184"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ajulo, S., and Awosile, B. (2024). Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0297921"},{"key":"ref_20","unstructured":"Centers for Disease Control and Prevention (CDC) (2026, March 15). Antimicrobial Resistance Facts and Stats, Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/facts-stats\/index.html."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Galgano, M., Pellegrini, F., Catalano, E., Capozzi, L., Del Sambro, L., Sposato, A., Lucente, M.S., Vasinioti, V.I., Catella, C., and Odigie, A.E. (2025). Acquired Bacterial Resistance to Antibiotics and Resistance Genes: From Past to Future. Antibiotics, 14.","DOI":"10.3390\/antibiotics14030222"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100081","DOI":"10.1016\/j.glmedi.2024.100081","article-title":"Antimicrobial resistance: Impacts, challenges, and future prospects","volume":"2","author":"Ahmed","year":"2024","journal-title":"J. Med. Surg. Public Health"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Roszkowska, M. (2024). Multilevel Mechanisms of Cancer Drug Resistance. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212402"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7555\/JBR.37.20230248","article-title":"Drug resistance mechanisms in cancers: Execution of pro-survival strategies","volume":"38","author":"Dhanyamraju","year":"2024","journal-title":"J. Biomed. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/1535-7163.MCT-07-2387","article-title":"The T790M \u201cgatekeeper\u201d mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor","volume":"7","author":"Ulkus","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., and Mangino, G. (2020). Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers, 12.","DOI":"10.3390\/cancers12102801"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101801","DOI":"10.1016\/j.gendis.2025.101801","article-title":"Platinum-resistant ovarian cancer: From mechanisms to treatment strategies","volume":"13","author":"Li","year":"2026","journal-title":"Genes Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/2159-8290.CD-20-1588","article-title":"Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment","volume":"11","author":"Russo","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","article-title":"Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors","volume":"56","author":"Michaeli","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s44259-025-00123-1","article-title":"Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria","volume":"3","author":"Gargate","year":"2025","journal-title":"npj Antimicrob. Resist."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/ncomms3467","article-title":"Non-Darwinian dynamics in therapy-induced cancer drug resistance","volume":"4","author":"Pisco","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.2147\/IDR.S290835","article-title":"Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health","volume":"13","author":"Majumder","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Olivares, J., Bernardini, A., Garcia-Leon, G., Corona, F., Sanchez, M.B., and Martinez, J.L. (2013). The intrinsic resistome of bacterial pathogens. Front. Microbiol., 4.","DOI":"10.3389\/fmicb.2013.00103"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijmm.2013.02.009","article-title":"Intrinsic antibiotic resistance: Mechanisms, origins, challenges and solutions","volume":"303","author":"Cox","year":"2013","journal-title":"Int. J. Med. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100947","DOI":"10.1016\/j.lanmic.2024.07.010","article-title":"Antimicrobial resistance: A concise update","volume":"6","author":"Ho","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sartori, M., Toppo, S., and Lavezzo, E. (2026). Molecular resistance mechanisms to newly approved antibiotics (2017\u20132025) in WHO priority pathogens. Front. Microbiol., 16, Correction in Front. Microbiol. 2026, 17, 1793977.","DOI":"10.3389\/fmicb.2025.1719798"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e082681","DOI":"10.1136\/bmj-2024-082681","article-title":"Antimicrobial use and resistance","volume":"391","author":"Reza","year":"2025","journal-title":"BMJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/AAC.37.10.2045","article-title":"Penicillin-binding proteins and bacterial resistance to beta-lactams","volume":"37","author":"Georgopapadakou","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1021\/acsinfecdis.1c00318","article-title":"Vancomyxins: Vancomycin-Polymyxin Nonapeptide Conjugates That Retain Anti-Gram-Positive Activity with Enhanced Potency against Gram-Negative Strains","volume":"7","author":"Slingerland","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Glen, K.A., and Lamont, I.L. (2021). \u03b2-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects. Pathogens, 10.","DOI":"10.3390\/pathogens10121638"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Mancuso, G., Midiri, A., Gerace, E., and Biondo, C. (2021). Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens, 10.","DOI":"10.3390\/pathogens10101310"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(15)00473-0","article-title":"Understanding the mechanisms and drivers of antimicrobial resistance","volume":"387","author":"Holmes","year":"2016","journal-title":"Lancet"},{"key":"ref_46","first-page":"81","article-title":"Towards an integrated model of bacterial conjugation","volume":"39","author":"Arechaga","year":"2015","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Baran, A., Kwiatkowska, A., and Potocki, L. (2023). Antibiotics and Bacterial Resistance\u2014A Short Story of an Endless Arms Race. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065777"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Belay, W.Y., Getachew, M., Tegegne, B.A., Teffera, Z.H., Dagne, A., Zeleke, T.K., Abebe, R.B., Gedif, A.A., Fenta, A., and Yirdaw, G. (2024). Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: A review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1444781"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/wsbm.1335","article-title":"Adaptive resistance to antibiotics in bacteria: A systems biology perspective","volume":"8","author":"Aldana","year":"2016","journal-title":"WIREs Syst. Biol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12275-019-0718-8","article-title":"Perspectives towards antibiotic resistance: From molecules to population","volume":"57","author":"Lee","year":"2019","journal-title":"J. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CMR.00043-12","article-title":"Adaptive and mutational resistance: Role of porins and efflux pumps in drug resistance","volume":"25","author":"Hancock","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Birlutiu, V., and Birlutiu, R.M. (2025). An Overview of the Epidemiology of Multidrug Resistance and Bacterial Resistance Mechanisms: What Solutions Are Available? A Comprehensive Review. Microorganisms, 13.","DOI":"10.3390\/microorganisms13092194"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/S1470-2045(25)00079-8","article-title":"Antimicrobial resistance in patients with haematological malignancies: A scoping review","volume":"26","author":"Sallah","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108163","DOI":"10.1016\/j.micpath.2025.108163","article-title":"Breaking barriers in antimicrobial therapy: Resistance mechanisms and novel antimicrobial strategies","volume":"210","author":"Suruchi","year":"2026","journal-title":"Microb. Pathog."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s43856-025-01090-4","article-title":"A One Health framework for global and local stewardship across the antimicrobial lifecycle","volume":"5","author":"Altevogt","year":"2025","journal-title":"Commun. Med."},{"key":"ref_56","unstructured":"World Health Organization (2026, March 15). Global Cancer Burden Growing, Amidst Mounting Need for Services. WHO News Release. Available online: https:\/\/www.who.int\/news\/item\/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-019-0044-1","article-title":"The great escape: Tumour cell plasticity in resistance to targeted therapy","volume":"19","author":"Boumahdi","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_59","first-page":"447","article-title":"Drug-adapted cancer cell lines as preclinical models of acquired resistance","volume":"2","author":"Michaelis","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bou Antoun, N., and Chioni, A.M. (2023). Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202307.1284.v1"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12964-020-00627-5","article-title":"Drug resistance and Cancer stem cells","volume":"19","author":"Li","year":"2021","journal-title":"Cell Commun. Signal"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Emran, T.B., Shahriar, A., Mahmud, A.R., Rahman, T., Abir, M.H., Siddiquee, M.F., Ahmed, H., Rahman, N., Nainu, F., and Wahyudin, E. (2022). Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.891652"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","article-title":"Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies","volume":"81","author":"Wajapeyee","year":"2021","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15365","DOI":"10.1038\/s41598-019-51981-5","article-title":"Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients","volume":"9","author":"Bray","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41568-025-00824-9","article-title":"Acquired resistance in cancer: Towards targeted therapeutic strategies","volume":"25","author":"Soragni","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-018-9903-0","article-title":"The challenge of drug resistance in cancer treatment: A current overview","volume":"35","author":"Nikolaou","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_67","first-page":"107","article-title":"Blueprint for cancer research: Critical gaps and opportunities","volume":"71","author":"Elmore","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"188310","DOI":"10.1016\/j.bbcan.2019.188310","article-title":"Mechanisms of acquired tumor drug resistance","volume":"1872","author":"Aleksakhina","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/onc.2014.314","article-title":"Mechanism-based cancer therapy: Resistance to therapy, therapy for resistance","volume":"34","author":"Ramos","year":"2015","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"122907","DOI":"10.1016\/j.lfs.2024.122907","article-title":"Drug resistance in human cancers\u2014Mechanisms and implications","volume":"352","author":"Vijayakumar","year":"2024","journal-title":"Life Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: Landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hassan, A., and Aubel, C. (2025). The PI3K\/Akt\/mTOR Signaling Pathway in Triple-Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17132232"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"104111","DOI":"10.1016\/j.redox.2026.104111","article-title":"A Clinical Decision Framework for Redox-Adapted, EMT-High Cancers: From Ferroptosis Resistance to Precision Therapeutic Stratification","volume":"92","author":"Park","year":"2026","journal-title":"Redox Biol."},{"key":"ref_75","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug. Resist."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e71244","DOI":"10.1002\/cam4.71244","article-title":"Metabolic Reprogramming of Cancer Cells and Therapeutics Targeting Cancer Metabolism","volume":"14","author":"Punnasseril","year":"2025","journal-title":"Cancer Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100797","DOI":"10.1016\/j.drup.2021.100797","article-title":"Impact of cancer metabolism on therapy resistance\u2014Clinical implications","volume":"59","author":"Richiardone","year":"2021","journal-title":"Drug Resist. Updates"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: Hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell. Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.drup.2019.100646","article-title":"The emergence of drug resistance to targeted cancer therapies: Clinical evidence","volume":"47","author":"Scorilas","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s11912-025-01718-7","article-title":"Host-related Determinants of Response to Immunotherapy in Non-small Cell Lung Cancer: The Interplay of Body Composition, Metabolism, Sex and Immune Regulation","volume":"27","author":"Santo","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jama.1946.02870380008004","article-title":"Nitrogen mustard therapy: Use of methyl-bis(\u03b2-chloroethyl)amine hydrochloride and tris(\u03b2-chloroethyl)amine hydrochloride for Hodgkin\u2019s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"JAMA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Chifiriuc, M.C., Filip, R., Constantin, M., Pircalabioru, G.G., Bleotu, C., Burlibasa, L., Ionica, E., Corcionivoschi, N., and Mihaescu, G. (2022). Common themes in antimicrobial and anticancer drug resistance. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.960693"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2958.2000.01926.x","article-title":"Multidrug resistance mechanisms: Drug efflux across two membranes","volume":"37","author":"Zgurskaya","year":"2000","journal-title":"Mol. Microbiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e20360","DOI":"10.7717\/peerj.20360","article-title":"Efflux systems driving resistance and virulence across biological domains","volume":"13","author":"Ramis","year":"2025","journal-title":"PeerJ"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Huang, L., Wu, C., Gao, H., Xu, C., Dai, M., Huang, L., Hao, H., Wang, X., and Cheng, G. (2022). Bacterial Multidrug Efflux Pumps at the Frontline of Antimicrobial Resistance: An Overview. Antibiotics, 11.","DOI":"10.3390\/antibiotics11040520"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2165\/11317030-000000000-00000","article-title":"Efflux-mediated drug resistance in bacteria: An update","volume":"69","author":"Li","year":"2009","journal-title":"Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"106182","DOI":"10.1016\/j.micpath.2023.106182","article-title":"Role of bacterial efflux pump proteins in antibiotic resistance across microbial species","volume":"181","author":"Kumawat","year":"2023","journal-title":"Microb. Pathog."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41579-018-0048-6","article-title":"Multidrug efflux pumps: Structure, function and regulation","volume":"16","author":"Du","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.resmic.2018.02.002","article-title":"Trans-envelope multidrug efflux pumps of Gram-negative bacteria and their synergism with the outer membrane barrier","volume":"169","author":"Zgurskaya","year":"2018","journal-title":"Microbiol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114137","DOI":"10.1016\/j.bcp.2020.114137","article-title":"Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K\/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines","volume":"180","author":"Wu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Skinner, K.T., Palkar, A.M., and Hong, A.L. (2023). Genetics of ABCB1 in Cancer. Cancers, 15.","DOI":"10.3390\/cancers15174236"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5732\/cjc.011.10320","article-title":"Breast cancer resistance protein (BCRP\/ABCG2): Its role in multidrug resistance and regulation of its gene expression","volume":"31","author":"Nakanishi","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"30880","DOI":"10.1074\/jbc.R114.609248","article-title":"Multidrug resistance protein 1 (MRP1, ABCC1), a \u201cmultitasking\u201d ATP-binding cassette (ABC) transporter","volume":"289","author":"Cole","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2016.03.001","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/1040841X.2019.1607248","article-title":"Tackling drug resistance with efflux pump inhibitors: From bacteria to cancerous cells","volume":"45","author":"Lowrence","year":"2019","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/acs.accounts.0c00843","article-title":"Multidrug Efflux Pumps and the Two-Faced Janus of Substrates and Inhibitors","volume":"54","author":"Zgurskaya","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"001333","DOI":"10.1099\/mic.0.001333","article-title":"Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors","volume":"169","author":"Gaurav","year":"2023","journal-title":"Microbiology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"24450","DOI":"10.1039\/D5RA04047G","article-title":"Small-molecule strategies to combat antibiotic resistance: Mechanisms, modifications, and contemporary approaches","volume":"15","author":"Elkady","year":"2025","journal-title":"RSC Adv."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"108488","DOI":"10.1016\/j.pharmthera.2023.108488","article-title":"Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review","volume":"249","author":"Dong","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"189272","DOI":"10.1016\/j.bbcan.2025.189272","article-title":"Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies","volume":"1880","author":"Pan","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/s10637-025-01562-3","article-title":"Advanced strategies to overcome multidrug resistance in cancer therapy: Progress in P-glycoprotein inhibitors, drug delivery, and personalized medicine","volume":"43","author":"Harish","year":"2025","journal-title":"Investig. New Drugs"},{"key":"ref_109","first-page":"6030","article-title":"Medicinal Chemistry Updates on Bacterial Efflux Pump Modulators","volume":"25","author":"Pinto","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s43556-025-00352-w","article-title":"Drug resistance in cancer: Molecular mechanisms and emerging treatment strategies","volume":"6","author":"Li","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wong, A. (2017). Epistasis and the Evolution of Antimicrobial Resistance. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00246"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Johnning, A., Kristiansson, E., Fick, J., Weijdeg\u00e5rd, B., and Larsson, D.G.J. (2015). Resistance Mutations in gyrA and parC are Common in Escherichia Communities of both Fluoroquinolone-Polluted and Uncontaminated Aquatic Environments. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.01355"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.addr.2005.04.003","article-title":"Bacterial resistance to antibiotics: Modified target sites","volume":"57","author":"Lambert","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molmed.2020.05.001","article-title":"Antibiotic Resistance by Enzymatic Modification of Antibiotic Targets","volume":"26","author":"Schaenzer","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e2208344120","DOI":"10.1073\/pnas.2208344120","article-title":"Antidepressants can induce mutation and enhance persistence toward multiple antibiotics","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","article-title":"Toward a Better Understanding of the Complexity of Cancer Drug Resistance","volume":"56","author":"Gottesman","year":"2016","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"101173","DOI":"10.1016\/j.drup.2024.101173","article-title":"Post-translational modifications in drug resistance","volume":"78","author":"Miao","year":"2025","journal-title":"Drug Resist. Updates"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"107438","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm"},{"key":"ref_120","first-page":"27","article-title":"Acquired resistance to molecularly targeted therapies for cancer","volume":"8","author":"Stubbs","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"a025239","DOI":"10.1101\/cshperspect.a025239","article-title":"\u03b2-Lactamases: A Focus on Current Challenges","volume":"7","author":"Bonomo","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"13523","DOI":"10.1021\/acs.jafc.4c02677","article-title":"Microbial Degradation of Tetracycline Antibiotics: Mechanisms and Environmental Implications","volume":"72","author":"Li","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.femsre.2004.04.001","article-title":"Molecular basis of bacterial resistance to chloramphenicol and florfenicol","volume":"28","author":"Schwarz","year":"2004","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Varela, M.F., Stephen, J., Lekshmi, M., Ojha, M., Wenzel, N., Sanford, L.M., Hernandez, A.J., Parvathi, A., and Kumar, S.H. (2021). Bacterial Resistance to Antimicrobial Agents. Antibiotics, 10.","DOI":"10.3390\/antibiotics10050593"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.8153624","article-title":"Inactivation of antibiotics and the dissemination of resistance genes","volume":"264","author":"Davies","year":"1994","journal-title":"Science"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s44259-025-00152-w","article-title":"Predicting drug inactivation by changes in bacterial growth dynamics","volume":"3","author":"Li","year":"2025","journal-title":"npj Antimicrob. Resist."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/03602532.2019.1632886","article-title":"Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it","volume":"51","author":"Verma","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/metabo5040571","article-title":"Cancer Metabolism and Drug Resistance","volume":"5","author":"Rahman","year":"2015","journal-title":"Metabolites"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activity","volume":"13","author":"Xu","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-fu metabolism in cancer and orally-administrable 5-fu drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","article-title":"Nucleoside analogues and nucleobases in cancer treatment","volume":"3","author":"Galmarini","year":"2002","journal-title":"Lancet Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"109448","DOI":"10.1016\/j.cbi.2021.109448","article-title":"Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance","volume":"340","author":"Hofman","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2217\/14622416.7.4.575","article-title":"Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8","volume":"7","author":"Pizarro","year":"2006","journal-title":"Pharmacogenomics"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.canlet.2018.06.028","article-title":"The multifaceted role of glutathione S-transferases in cancer","volume":"433","author":"Chatterjee","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjc.2014.386","article-title":"Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines","volume":"111","author":"Sawers","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"16582","DOI":"10.1074\/jbc.M109.090506","article-title":"Glutathione Transport Is a Unique Function of the ATP-binding Cassette Protein ABCG2","volume":"285","author":"Brechbuhl","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-9-46","article-title":"Pregnane \u00d7 Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation","volume":"9","author":"Raynal","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biopha.2018.05.117","article-title":"Drug metabolizing enzymes and their inhibitors\u2019 role in cancer resistance","volume":"105","author":"Pathania","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e1411","DOI":"10.1038\/cddis.2014.378","article-title":"UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib","volume":"5","author":"Landmann","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_141","first-page":"2888","article-title":"Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations","volume":"8","author":"Rodriguez","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Mendes, I., and Vale, N. (2023). How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411855"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"218305","DOI":"10.1016\/j.canlet.2026.218305","article-title":"The role of the microbiota in cancer drug resistance and emerging therapeutic strategies","volume":"642","author":"Che","year":"2026","journal-title":"Cancer Lett."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.tips.2026.01.013","article-title":"Targeting metabolism to combat anticancer and antibacterial drug resistance","volume":"4","author":"Chung","year":"2026","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"100617","DOI":"10.1016\/j.microb.2025.100617","article-title":"Antimicrobial resistance: Mechanism, causes, prevention and societal impact","volume":"9","author":"Baweja","year":"2025","journal-title":"Microbe"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s44320-025-00087-4","article-title":"Epigenetic modifications and metabolic gene mutations drive resistance evolution in response to stimulatory antibiotics","volume":"21","author":"Lin","year":"2025","journal-title":"Mol. Syst. Biol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Sherif, Z.A., Ogunwobi, O.O., and Ressom, H.W. (2024). Mechanisms and technologies in cancer epigenetics. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1513654"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/1947601910393957","article-title":"DNA methylation: Superior or subordinate in the epigenetic hierarchy?","volume":"2","author":"Jin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","article-title":"DNA methylation and human disease","volume":"6","author":"Robertson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-15-3449-2_1","article-title":"Epigenetics in Health and Disease","volume":"1253","author":"Zhang","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"100729","DOI":"10.1016\/j.drup.2020.100729","article-title":"The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology","volume":"53","author":"Assaraf","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.semcancer.2018.01.007","article-title":"Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine","volume":"51","author":"Pasculli","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/bs.acr.2022.12.006","article-title":"Epigenetic adaptations in drug-tolerant tumor cells","volume":"158","author":"Mani","year":"2023","journal-title":"Adv. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.semcancer.2020.12.022","article-title":"Targeting epigenetic regulatory machinery to overcome cancer therapy resistance","volume":"83","author":"Guo","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"e02225-19","DOI":"10.1128\/AAC.02225-19","article-title":"Antibiotic Resistance and Epigenetics: More to It than Meets the Eye","volume":"64","author":"Ghosh","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Wang, X., Yu, D., and Chen, L. (2023). Antimicrobial resistance and mechanisms of epigenetic regulation. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1199646"},{"key":"ref_159","first-page":"3036","article-title":"Genome-wide DNA methylation and transcriptome changes in Mycobacterium tuberculosis with rifampicin and isoniazid resistance","volume":"11","author":"Chen","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/cbdd.13625","article-title":"Genome-wide DNA methylation and transcriptome and proteome changes in Mycobacterium tuberculosis with para-aminosalicylic acid resistance","volume":"95","author":"Li","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Cota, I., S\u00e1nchez-Romero, M.A., Hern\u00e1ndez, S.B., Pucciarelli, M.G., Garc\u00eda-Del Portillo, F., and Casades\u00fas, J. (2015). Epigenetic Control of Salmonella enterica O-Antigen Chain Length: A Tradeoff between Virulence and Bacteriophage Resistance. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1005667"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"16470","DOI":"10.1073\/pnas.182427199","article-title":"Self-perpetuating epigenetic pili switches in bacteria","volume":"99","author":"Hernday","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1128\/AAC.00004-14","article-title":"Phasevarions mediate epigenetic regulation of antimicrobial susceptibility in Neisseria meningitidis","volume":"58","author":"Jen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Motta, S.S., Cluzel, P., and Aldana, M. (2015). Adaptive resistance in bacteria requires epigenetic inheritance, genetic noise, and cost of efflux pumps. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118464"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1128\/AEM.00900-15","article-title":"Phenotypic Heterogeneity, a Phenomenon That May Explain Why Quorum Sensing Does Not Always Result in Truly Homogenous Cell Behavior","volume":"81","author":"Grote","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/mec.13603","article-title":"Interpreting phenotypic antibiotic tolerance and persister cells as evolution via epigenetic inheritance","volume":"25","author":"Day","year":"2016","journal-title":"Mol. Ecol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/MMBR.00016-06","article-title":"Epigenetic gene regulation in the bacterial world","volume":"70","author":"Low","year":"2006","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00018-013-1487-x","article-title":"Influence of bacteria on epigenetic gene control","volume":"71","author":"Takahashi","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1002\/mco2.495","article-title":"Epigenetic regulation in cancer","volume":"5","author":"Gu","year":"2024","journal-title":"MedComm"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"BSR20211812","DOI":"10.1042\/BSR20211812","article-title":"The paradigm of drug resistance in cancer: An epigenetic perspective","volume":"42","author":"Adhikari","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Holden, E.R., and Webber, M.A. (2020). MarA, RamA, and SoxS as Mediators of the Stress Response: Survival at a Cost. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00828"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"ftx080","DOI":"10.1093\/femspd\/ftx080","article-title":"Phase variation of DNA methyltransferases and the regulation of virulence and immune evasion in the pathogenic Neisseria","volume":"75","author":"Seib","year":"2017","journal-title":"Pathog. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: From the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Acierno, C., Barletta, F., Nevola, R., Rinaldi, L., Sasso, F.C., Adinolfi, L.E., and Caturano, A. (2025). Metabolic Rewiring of Bacterial Pathogens in Response to Antibiotic Pressure-A Molecular Perspective. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125574"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.freeradbiomed.2020.10.322","article-title":"The alarmone (p)ppGpp confers tolerance to oxidative stress during the stationary phase by maintenance of redox and iron homeostasis in Staphylococcus aureus","volume":"161","author":"Fritsch","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e0003622","DOI":"10.1128\/mmbr.00036-22","article-title":"Aminoglycoside uptake, stress, and potentiation in Gram-negative bacteria: New therapies with old molecules","volume":"87","author":"Lang","year":"2023","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/CMR.00069-15","article-title":"Clinical Significance and Pathogenesis of Staphylococcal Small Colony Variants in Persistent Infections","volume":"29","author":"Kahl","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00204-024-03696-4","article-title":"Several lines of antioxidant defense against oxidative stress: Antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants","volume":"98","author":"Jomova","year":"2024","journal-title":"Arch. Toxicol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"402","DOI":"10.31083\/j.fbl2912402","article-title":"The Warburg Effect: Is it Always an Enemy?","volume":"29","author":"Papaneophytou","year":"2024","journal-title":"Front. Biosci."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Khan, T., Nagarajan, M., Kang, I., Wu, C., and Wangpaichitr, M. (2025). Targeting Metabolic Vulnerabilities to Combat Drug Resistance in Cancer Therapy. J. Pers. Med., 15.","DOI":"10.3390\/jpm15020050"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41420-025-02554-1","article-title":"The role and mechanism of fatty acid oxidation in cancer drug resistance","volume":"11","author":"Lei","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12964-023-01449-x","article-title":"Glutamine addiction in tumor cell: Oncogene regulation and clinical treatment","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s11427-017-9178-y","article-title":"Hypoxia inducible factor (HIF) in the tumor microenvironment: Friend or foe?","volume":"60","author":"Huang","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.chom.2013.05.009","article-title":"Microbial persistence and the road to drug resistance","volume":"13","author":"Cohen","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4143\/crt.2023.468","article-title":"Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies","volume":"55","author":"Min","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Kunnath, A.P., Suodha Suoodh, M., Chellappan, D.K., Chellian, J., and Palaniveloo, K. (2024). Bacterial Persister Cells and Development of Antibiotic Resistance in Chronic Infections: An Update. Br. J. Biomed. Sci., 81.","DOI":"10.3389\/bjbs.2024.12958"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(00)74210-3","article-title":"Treatment of staphylococcal infections with penicillin by intermittent sterilisation","volume":"244","author":"Bigger","year":"1944","journal-title":"Lancet"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41392-024-01866-5","article-title":"Bacterial persisters: Molecular mechanisms and therapeutic development","volume":"9","author":"Niu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Yuan, S., Shen, Y., Quan, Y., Gao, S., Zuo, J., Jin, W., Li, R., Yi, L., Wang, Y., and Wang, Y. (2024). Molecular mechanism and application of emerging technologies in study of bacterial persisters. BMC Microbiol., 24.","DOI":"10.1186\/s12866-024-03628-3"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Li, L., Mendis, N., Trigui, H., Oliver, J.D., and Faucher, S.P. (2014). The importance of the viable but non-culturable state in human bacterial pathogens. Front. Microbiol., 5.","DOI":"10.3389\/fmicb.2014.00258"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"100444","DOI":"10.1016\/j.microb.2025.100444","article-title":"Advances in research on small colony variants of Staphylococcus aureus","volume":"8","author":"Ye","year":"2025","journal-title":"Microbe"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12943-025-02323-9","article-title":"Drug-induced tolerant persisters in tumor: Mechanism, vulnerability and perspective implication for clinical treatment","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"216899","DOI":"10.1016\/j.canlet.2024.216899","article-title":"Unveiling cancer dormancy: Intrinsic mechanisms and extrinsic forces","volume":"591","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S1473-3099(21)00122-5","article-title":"The importance of understanding the infectious microenvironment","volume":"22","author":"Bjarnsholt","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Dzobo, K., Senthebane, D.A., and Dandara, C. (2023). The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited. Cancers, 15.","DOI":"10.3390\/cancers15020376"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Zhao, A., Sun, J., and Liu, Y. (2023). Understanding bacterial biofilms: From definition to treatment strategies. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1137947"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41522-024-00544-2","article-title":"Effect of biofilm physical characteristics on their susceptibility to antibiotics: Impacts of low-frequency ultrasound","volume":"10","author":"Nahum","year":"2024","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1705814","DOI":"10.1155\/2020\/1705814","article-title":"The Role of Bacterial Biofilm in Antibiotic Resistance and Food Contamination","volume":"2020","author":"Abebe","year":"2020","journal-title":"Int. J. Microbiol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e0104225","DOI":"10.1128\/jcm.01042-25","article-title":"Biofilms in clinical infection: Pathophysiology, diagnosis, and the evolving therapeutic landscape","volume":"64","author":"Domouchtsidou","year":"2026","journal-title":"J. Clin. Microbiol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s44259-025-00113-3","article-title":"Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing","volume":"3","author":"Chu","year":"2025","journal-title":"npj Antimicrob. Resist."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-024-00482-x","article-title":"Cancer metabolism and carcinogenesis","volume":"13","author":"Yang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12943-025-02533-1","article-title":"Cancer-associated fibroblasts in the tumor microenvironment: Heterogeneity, crosstalk mechanisms, and therapeutic implications","volume":"25","author":"Huang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41420-025-02566-x","article-title":"Cancer-associated fibroblasts in cancer drug resistance and cancer progression: A review","volume":"11","author":"Masuda","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_207","first-page":"e70700","article-title":"Hypoxia-Inducible Factor 1-Alpha (HIF-1\u03b1) and Cancer: Mechanisms of Tumor Hypoxia and Therapeutic Targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e934116","DOI":"10.12659\/MSM.934116","article-title":"A Review of the Role of Hypoxia in Radioresistance in Cancer Therapy","volume":"27","author":"Bouleftour","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"e70098","DOI":"10.1002\/ctd2.70098","article-title":"Reprogramming the tumour microenvironment: Emerging strategies to overcome immunotherapy resistance","volume":"5","author":"Elbadri","year":"2025","journal-title":"Clin. Transl. Discov."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-022-00692-2","article-title":"Gradients and consequences of heterogeneity in biofilms","volume":"20","author":"Jo","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrmicro1838","article-title":"Physiological heterogeneity in biofilms","volume":"6","author":"Stewart","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-Inducible Factors in Physiology and Medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2174\/0929867013371743","article-title":"Efflux pumps: Their role in antibacterial drug discovery","volume":"8","author":"Lomovskaya","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s10096-024-04920-w","article-title":"An insight on the powerful of bacterial quorum sensing inhibition","volume":"43","author":"Naga","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"101322","DOI":"10.1016\/j.drup.2025.101322","article-title":"Metabolite-driven reprogramming of bacterial persisters: Mechanisms and therapeutic opportunities for overcoming antibiotic tolerance","volume":"84","author":"Song","year":"2026","journal-title":"Drug Resist. Updates"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/21505594.2017.1313372","article-title":"Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action","volume":"9","author":"Roy","year":"2018","journal-title":"Virulence"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2604867","DOI":"10.1080\/19490976.2025.2604867","article-title":"Microbes and medicines: Interrelationships between pharmaceuticals and the gut microbiome","volume":"18","author":"Donnelly","year":"2026","journal-title":"Gut Microbes"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: The next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Sargianou, M., Stathopoulos, P., Vrysis, C., Tzvetanova, I.D., and Falagas, M.E. (2025). New \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination Antibiotics. Pathogens, 14.","DOI":"10.3390\/pathogens14040307"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2016.06.007","article-title":"Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials","volume":"28","author":"Blanco","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The Emerging Hallmarks of Cancer Metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2174\/1389450122666210614122352","article-title":"Combination Therapy as a Strategy to Control Infections Caused by Multi-resistant Bacteria: Current Review","volume":"23","author":"Baquero","year":"2022","journal-title":"Curr. Drug Targets"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"e01586-16","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"ref_226","doi-asserted-by":"crossref","unstructured":"Sep\u00falveda-Crespo, D., and Resino, S. (2025). From Management to Cure: The Shifting Paradigm in HIV and Chronic Viral Hepatitis. Pharmaceuticals, 18.","DOI":"10.3390\/ph18071034"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/03009734.2014.899279","article-title":"Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria","volume":"119","year":"2014","journal-title":"Upsala J. Med. Sci."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ejca.2005.01.006","article-title":"Survival in Hodgkin\u2019s disease patients\u2014Report of 25 years of experience at the Milan Cancer Institute","volume":"41","author":"Bonadonna","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat. Med."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/atm-25-34","article-title":"Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment","volume":"13","author":"Jamalinia","year":"2025","journal-title":"Ann. Transl. Med."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e0137322","DOI":"10.1128\/aac.01373-22","article-title":"Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","volume":"67","author":"Krajewska","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Reza, A., Sutton, J.M., and Rahman, K.M. (2019). Effectiveness of Efflux Pump Inhibitors as Biofilm Disruptors and Resistance Breakers in Gram-Negative (ESKAPEE) Bacteria. Antibiotics, 8.","DOI":"10.20944\/preprints201910.0255.v1"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Xu, F., Xie, Y., Yu, W., and Wang, Z. (2026). Breaking the outer membrane barrier: Structure, targets, and antimicrobial strategies for Gram-negative bacteria. Front. Microbiol., 17.","DOI":"10.3389\/fmicb.2026.1734749"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., and Khan, F.S. (2022). Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life, 12.","DOI":"10.3390\/life12060897"},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., and Shao, A. (2020). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00193"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Ebrahim, T., Ebrahim, A.S., and Kandouz, M. (2024). Diversity of Intercellular Communication Modes: A Cancer Biology Perspective. Cells, 13.","DOI":"10.3390\/cells13060495"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2415598","DOI":"10.1080\/19420889.2024.2415598","article-title":"Quorum sensing and antibiotic resistance in polymicrobial infections","volume":"17","author":"Cui","year":"2024","journal-title":"Commun. Integr. Biol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"108733","DOI":"10.1016\/j.biotechadv.2025.108733","article-title":"Microbial quorum sensing: Mechanisms, applications, and challenges","volume":"86","author":"Ruan","year":"2026","journal-title":"Biotechnol. Adv."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Papaneophytou, C. (2026). Phytochemical Quorum-Sensing Inhibitors Against Bacterial Pathogens: Mechanisms of Action and Translational Challenges. Curr. Issues Mol. Biol., 48.","DOI":"10.3390\/cimb48020214"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s11756-025-02006-2","article-title":"Targeting acyl homoserine lactone regulated quorum sensing by quorum quenching enzymes","volume":"80","author":"Patil","year":"2025","journal-title":"Biologia"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Panayi, T., Sarigiannis, Y., Mourelatou, E., Hapeshis, E., and Papaneophytou, C. (2022). Anti-Quorum-Sensing Potential of Ethanolic Extracts of Aromatic Plants from the Flora of Cyprus. Plants, 11.","DOI":"10.20944\/preprints202207.0425.v1"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/macromol4040045","article-title":"Targeting Bacterial Communication: Evaluating Phytochemicals as LuxS Inhibitors to Disrupt Quorum Sensing","volume":"4","author":"Sarigiannis","year":"2024","journal-title":"Macromol"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00203-024-03900-0","article-title":"Unveiling the hidden language of bacteria: Anti-quorum sensing strategies for gram-negative bacteria infection control","volume":"206","author":"Elfaky","year":"2024","journal-title":"Arch. Microbiol."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","article-title":"Chemoresistance and the tumor microenvironment: The critical role of cell-cell communication","volume":"22","author":"Kulbacka","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"ref_246","doi-asserted-by":"crossref","unstructured":"Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., and Ma, X. (2021). The Role of Tumor-Stroma Interactions in Drug Resistance within Tumor Microenvironment. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.637675"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_248","first-page":"457","article-title":"Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets","volume":"2","author":"Murayama","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Stojowska-Sw\u0119drzy\u0144ska, K., Kuczy\u0144ska-Wi\u015bnik, D., and Laskowska, E. (2023). New Strategies to Kill Metabolically-Dormant Cells Directly Bypassing the Need for Active Cellular Processes. Antibiotics, 12.","DOI":"10.3390\/antibiotics12061044"},{"key":"ref_250","first-page":"100047","article-title":"Bacterial toxin-antitoxin modules: Classification, functions, and association with persistence","volume":"2","author":"Singh","year":"2021","journal-title":"Curr. Res. Microb. Sci."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Gli\u017aniewicz, M., Mi\u0142ek, D., Olszewska, P., Czajkowski, A., Serwin, N., Cecerska-Hery\u0107, E., Do\u0142\u0119gowska, B., and Grygorcewicz, B. (2023). Advances in bacteriophage-mediated strategies for combating polymicrobial biofilms. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1320345"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update","volume":"12","author":"Takebe","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10555-023-10081-7","article-title":"The role of cancer cell bioenergetics in dormancy and drug resistance","volume":"42","author":"Tau","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"42460","DOI":"10.1039\/D5RA04206B","article-title":"Nanoparticle-mediated approaches to combat antibiotic resistance: A comprehensive review on current progress, mechanisms, and future perspectives","volume":"15","author":"Hayat","year":"2025","journal-title":"RSC Adv."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Spirescu, V.A., Chircov, C., Grumezescu, A.M., and Andronescu, E. (2021). Polymeric Nanoparticles for Antimicrobial Therapies: An Up-To-Date Overview. Polymers, 13.","DOI":"10.3390\/polym13050724"},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Wahab, S., Salman, A., Khan, Z., Khan, S., Krishnaraj, C., and Yun, S.-I. (2023). Metallic Nanoparticles: A Promising Arsenal against Antimicrobial Resistance\u2014Unraveling Mechanisms and Enhancing Medication Efficacy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914897"},{"key":"ref_257","first-page":"100156","article-title":"Nanoparticles targeting biofilms: A new era in combating antimicrobial resistance","volume":"26","author":"Joshi","year":"2025","journal-title":"Med. Microec."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"e10293","DOI":"10.1002\/adma.202510293","article-title":"Nanomedicine Reimagined: Translational Strategies for Precision Tumor Theranostics","volume":"38","author":"Wu","year":"2026","journal-title":"Adv. Mater."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Miguel, R.D.A., Hirata, A.S., Jimenez, P.C., Lopes, L.B., and Costa-Lotufo, L.V. (2022). Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14081722"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17435889.2025.2466409","article-title":"Emerging nanocarriers as advanced delivery tools for the treatment of leukemia","volume":"20","author":"Sen","year":"2025","journal-title":"Nanomedicine"},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., and Shen, J. (2025). Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers, 17.","DOI":"10.3390\/polym17081010"},{"key":"ref_262","first-page":"61","article-title":"Nanotherapeutic strategies exploiting biological traits of cancer stem cells","volume":"50","author":"Wang","year":"2025","journal-title":"Bioact. Mater."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug Repurposing: An Effective Tool in Modern Drug Discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"12019","DOI":"10.2147\/DDDT.S576701","article-title":"Drug Repurposing as an Effective Drug Discovery Strategy: A Critical Review","volume":"19","author":"Wali","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Tiwana, G., Cock, I.E., Taylor, S.M., and Cheesman, M.J. (2025). Beyond Antibiotics: Repurposing Non-Antibiotic Drugs as Novel Antibacterial Agents to Combat Resistance. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26209880"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.2147\/IDR.S490998","article-title":"Drug Repurposing: Research Progress of Niclosamide and Its Derivatives on Antibacterial Activity","volume":"17","author":"Liu","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_267","doi-asserted-by":"crossref","unstructured":"Niazy, A.A., Alrashed, M.M., Lambarte, R.N.A., and Niazy, A.A. (2024). 5-Fluorouracil Inhibits Bacterial Growth and Reduces Biofilm in Addition to Having Synergetic Effects with Gentamicin Against Pseudomonas aeruginosa. Microorganisms, 12.","DOI":"10.3390\/microorganisms12112257"},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Mucha, P., Borkowski, B., Erkiert-Polguj, A., and Budzisz, E. (2024). Ciclopirox and Ciclopirox Olamine: Antifungal Agents in Dermatology with Expanding Therapeutic Potential. Appl. Sci., 14.","DOI":"10.3390\/app142411859"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/17568919.2025.2453422","article-title":"The antimicrobial activity of auranofin and other gold complexes","volume":"17","author":"Chen","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_270","doi-asserted-by":"crossref","unstructured":"R\u00e1cz, B., and Spengler, G. (2023). Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010137"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"102068","DOI":"10.1016\/j.mcp.2026.102068","article-title":"Metformin and oncogenic pathways: Crosstalk between energy sensing and tumor progression","volume":"86","author":"Zhang","year":"2026","journal-title":"Mol. Cell. Probes"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.2147\/IJN.S458910","article-title":"Pharmacology Progresses and Applications of Chloroquine in Cancer Therapy","volume":"19","author":"Liu","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Robalino, K.N., Vivanco-Galv\u00e1n, O., Romero-Benavides, J.C., and Jim\u00e9nez-Gaona, Y. (2025). Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential. Pharmaceuticals, 18.","DOI":"10.3390\/ph18101459"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"166746","DOI":"10.1016\/j.bbadis.2023.166746","article-title":"Targeting the tumor microenvironment: Potential strategy for cancer therapeutics","volume":"1869","author":"Babar","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"108545","DOI":"10.1016\/j.ijid.2026.108545","article-title":"Host-directed Therapy for Tuberculosis: Repurposed Drugs towards Global Tuberculosis Elimination","volume":"167","author":"Wong","year":"2026","journal-title":"Int. J. Infect. Dis."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/imr.12951","article-title":"Host-directed therapy to combat mycobacterial infections","volume":"301","author":"Saris","year":"2021","journal-title":"Immunol. Rev."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"e70412","DOI":"10.1002\/mco2.70412","article-title":"The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances","volume":"6","author":"Chen","year":"2025","journal-title":"MedComm"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41423-026-01405-y","article-title":"T cell adaptation in chronic infections and tumors","volume":"23","author":"Luxenburger","year":"2026","journal-title":"Cell. Mol. Immunol."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Karamanolis, N.N., Kounatidis, D., Vallianou, N.G., Dimitriou, K., Tsaroucha, E., Tsioulos, G., Anastasiou, I.A., Mavrothalassitis, E., Karampela, I., and Dalamaga, M. (2025). Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives. Antibiotics, 14.","DOI":"10.3390\/antibiotics14010009"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"26762","DOI":"10.1021\/acsomega.4c00617","article-title":"Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery","volume":"9","author":"Bano","year":"2024","journal-title":"ACS Omega"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/BF00686191","article-title":"The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism","volume":"36","author":"Powers","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3892\/ijo.2013.1870","article-title":"Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells","volume":"42","author":"Moriya","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_284","doi-asserted-by":"crossref","unstructured":"Ferrario, N., Marras, E., Vivona, V., Randisi, F., Fallica, A.N., Marrazzo, A., Perletti, G., and Gariboldi, M.B. (2024). Mechanisms of the Antineoplastic Effects of New Fluoroquinolones in 2D and 3D Human Breast and Bladder Cancer Cell Lines. Cancers, 16.","DOI":"10.3390\/cancers16122227"},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Pfab, C., Schnobrich, L., Eldnasoury, S., Gessner, A., and El-Najjar, N. (2021). Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?. Cancers, 13.","DOI":"10.3390\/cancers13133193"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S1473-3099(16)00078-5","article-title":"Host-directed therapies for infectious diseases: Current status, recent progress, and future prospects","volume":"16","author":"Zumla","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41522-023-00427-y","article-title":"Strategy to combat biofilms: A focus on biofilm dispersal enzymes","volume":"9","author":"Wang","year":"2023","journal-title":"npj Biofilms Microbiomes"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-031-08491-1_3","article-title":"Controlling Biofilm Development Through Cyclic di-GMP Signaling","volume":"1386","author":"Park","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/17460441.2017.1331216","article-title":"Rational design strategies for FimH antagonists: New drugs on the horizon for urinary tract infection and Crohn\u2019s disease","volume":"12","author":"Hannan","year":"2017","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Husain, F.M., Zahra, A., Ali, A., Kamthan, M., Al-Shabib, N.A., Farooqui, Z., Ahmad, N., Albalawi, T., Alam, P., and Munawar, N. (2025). Bacteriophages and Their Enzymes: Allies Against Microbial Biofilms. Pharmaceuticals, 18.","DOI":"10.3390\/ph18121771"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13046-021-02070-x","article-title":"PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models","volume":"40","author":"Morosi","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12951-025-03815-y","article-title":"Collagenase-mediated extracellular matrix targeting for enhanced drug penetration and therapeutic efficacy in nanoscale delivery systems for cancer therapy","volume":"23","author":"Gong","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/cas.16443","article-title":"Targeting Cancer-Associated Fibroblasts: Eliminate or Reprogram?","volume":"116","author":"Yamazaki","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., and Maenhout, S.K. (2018). Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02909"},{"key":"ref_296","doi-asserted-by":"crossref","unstructured":"Fan, W., Shao, K., and Luo, M. (2024). Structural View of Cryo-Electron Microscopy-Determined ATP-Binding Cassette Transporters in Human Multidrug Resistance. Biomolecules, 14.","DOI":"10.3390\/biom14020231"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.trecan.2024.02.002","article-title":"Persisting cancer cells are different from bacterial persisters","volume":"10","author":"Decollogny","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Huang, K., Xu, Y., Feng, T., Lan, H., Ling, F., Xiang, H., and Liu, Q. (2024). The Advancement and Application of the Single-Cell Transcriptome in Biological and Medical Research. Biology, 13.","DOI":"10.3390\/biology13060451"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.csbj.2025.01.006","article-title":"The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance","volume":"27","author":"Bilal","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Scaglione, G., Mastroianni, N., Rizzo, A., Palomba, E., Carcione, D., Brigante, G., Principe, L., Colaneri, M., Gori, A., and Borgonovo, F. (2026). Integrating artificial intelligence with genome sequencing against antimicrobial resistance: A narrative review. Front. Public Health, 14, Correction in Front. Public Health 2026, 14, 1824508.","DOI":"10.3389\/fpubh.2026.1824508"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"30509","DOI":"10.1038\/s41598-025-14078-w","article-title":"Prediction of antibiotic resistance from antibiotic susceptibility testing results from surveillance data using machine learning","volume":"15","author":"Valavarasu","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-026-01276-6","article-title":"The impact of AI on modern oncology from early detection to personalized cancer treatment","volume":"10","author":"Li","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmp.2026.04.001","article-title":"Oncology drug resistance prediction tools: Database infrastructure, algorithmic innovation, and clinical translation","volume":"19","author":"Wang","year":"2026","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s44276-026-00221-1","article-title":"Precision oncology in the age of AI: Lessons from AI-driven drug discovery and clinical translation","volume":"4","author":"Yoo","year":"2026","journal-title":"BJC Rep."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12032-023-01968-0","article-title":"Modeling cancer\u2019s ecological and evolutionary dynamics","volume":"40","author":"Bukkuri","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Ribba, B. (2022). Reinforcement learning as an innovative model-based approach: Examples from precision dosing, digital health and computational psychiatry. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1094281"},{"key":"ref_307","doi-asserted-by":"crossref","unstructured":"Tavakoli, F., Mohammadpur, D., Sartakhti, J.S., and Manshaei, M.H. (2025). Reinforcement Learning-Driven Evolutionary Stackelberg Game Model for Adaptive Breast Cancer Therapy. Math. Comput. Appl., 30.","DOI":"10.3390\/mca30060134"},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Zhu, W., Zhu, M., Wang, W., Xu, L., Wu, J., Li, W., Ma, R., and Cao, L. (2026). Deep learning for adaptive chemotherapy: A DDPG-based approach to optimizing tumor-immune dynamics. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0345877"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"100132","DOI":"10.1016\/j.insi.2025.100132","article-title":"Harnessing AI-powered computational drug design to combat antimicrobial resistance: A comprehensive review of challenges, opportunities, and future directions","volume":"1","author":"Santhiya","year":"2025","journal-title":"Silico Res. Biomed."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.biomaterials.2018.10.030","article-title":"In vitro and ex vivo systems at the forefront of infection modeling and drug discovery","volume":"198","author":"Shi","year":"2019","journal-title":"Biomaterials"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_312","doi-asserted-by":"crossref","unstructured":"Maeda, T., and Furusawa, C. (2024). Laboratory Evolution of Antimicrobial Resistance in Bacteria to Develop Rational Treatment Strategies. Antibiotics, 13.","DOI":"10.3390\/antibiotics13010094"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Guo, Q., Bi, J., Lin, Q., Ye, T., Wang, Z., Wang, Z., Liu, L., and Zhang, G. (2022). Whole Genome Sequencing Identifies Novel Mutations Associated with Bedaquiline Resistance in Mycobacterium tuberculosis. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.807095"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tig.2014.07.003","article-title":"Whole-genome sequencing to control antimicrobial resistance","volume":"30","author":"Ellington","year":"2014","journal-title":"Trends Genet."},{"key":"ref_315","doi-asserted-by":"crossref","unstructured":"Motohashi, S., Katsuta, E., and Ban, D. (2025). Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review. Bioengineering, 12.","DOI":"10.3390\/bioengineering12121315"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","article-title":"Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance","volume":"18","author":"Cheng","year":"2025","journal-title":"J. Hematol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:12:27Z","timestamp":1779250347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":316,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104239"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104239","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]}}}